BioSpace News Archive

Histologics, LLC., a leader in the diagnostic field of tissue sampling, proudly welcomes Jannalee Johnson as their new Business Development Consultant for Gynecologic and Wound Care, effective Monday, July 24th, 2023.

McKesson Medical-Surgical, an affiliate of the McKesson Corporation, will participate as a silver sponsor of the National Association of Community Health Centers National Health Center Week 2023 Aug. 6-12.

Bionano Genomics, Inc. announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.

Mersana Therapeutics, Inc. announced that on August 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock and restricted stock unit awards to acquire an aggregate of 27,655 shares of its common stock, to two new employees whose employment commenced in July 2023.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 13 new employees with a grant date of August 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Rhythm Pharmaceuticals, Inc. announced that on August 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 39,720 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 26,480 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 13,240 shares of its common stock.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees stock options to purchase an aggregate of 38,600 shares, and restricted stock units covering an aggregate of 26,450 shares, of BioCryst common stock.

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that on August 1, 2023 the Company granted inducement awards to purchase up to 118,000 shares of common stock to nine new employees under the Company’s 2023 Inducement Plan.

Atara Biotherapeutics, Inc. reported the grant of 72,000 restricted stock units of Atara’s common stock to two newly hired employees.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to three new employees.